Buy Austedo (deutetrabenazine) deutetrabenazine

Austedo (deutetrabenazine) is an FDA-approved oral medication developed by Teva Neuroscience, Inc. for treating tardive dyskinesia and chorea associated with Huntington's disease. It received orphan drug designation for both indications, recognizing its therapeutic importance in rare movement disorders affecting the central nervous system.

Strength

6 mg/1

Pack Size

60 TABLET, COATED in 1 BOTTLE (68546-170-60)

Manufacturer / TM Owner

Teva Neuroscience, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Austedo is indicated for the treatment of tardive dyskinesia (TD), a potentially irreversible involuntary movement disorder often resulting from long-term antipsychotic medication use, and for chorea associated with Huntington's disease, a progressive neurodegenerative disorder. The drug targets patients experiencing hyperkinetic movement abnormalities characterized by repetitive, involuntary movements of the face, limbs, and trunk. Deutetrabenazine, the active ingredient, functions as a vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing the availability of dopamine and other monoamines in the presynaptic neuron. This mechanism helps diminish the excessive involuntary movements characteristic of both conditions. Austedo is administered orally and represents a significant therapeutic option for patients with limited treatment alternatives, particularly those with TD who cannot tolerate or discontinue causative antipsychotic medications.

Side Effects

Common side effects of Austedo include sedation, akathisia, depression, insomnia, and parkinsonism. Serious adverse events include suicidality, neuroleptic malignant syndrome (NMS), akathisia, and hepatic impairment. Patients require baseline and periodic monitoring of liver function tests, as hepatic disease may necessitate dose adjustment. Psychiatric monitoring is essential given the risk of depression and suicidal ideation. Blood pressure monitoring is recommended due to potential hypotensive effects. Regular assessment of movement disorders and neurological status should be conducted throughout treatment to evaluate therapeutic response and detect emerging adverse effects.

Precautions & Warnings

Austedo is contraindicated in patients with hepatic impairment, as deutetrabenazine undergoes hepatic metabolism. Caution is warranted in patients with cardiac conduction abnormalities, recent myocardial infarction, or uncontrolled hypertension. The drug carries a black box warning for increased suicidality risk, particularly in patients with depression or psychiatric history. Pregnancy category is not established; use only if benefits outweigh risks. Pediatric safety and efficacy have not been established. Renal impairment does not require dose adjustment, but hepatic impairment necessitates careful dosing consideration. Concurrent use with other CNS depressants may potentiate sedation and should be managed cautiously.

Avoid Interactions

Austedo should be used cautiously with strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine), which may increase deutetrabenazine exposure and adverse effects. Concurrent use with other VMAT2 inhibitors is not recommended. CNS depressants, including alcohol, opioids, and sedating medications, may potentiate sedation and impairment. Antipsychotics and other dopamine antagonists may reduce Austedo's efficacy. Monoamine oxidase inhibitors (MAOIs) are contraindicated. Patients should avoid alcohol consumption and inform healthcare providers of all concurrent medications to prevent clinically significant interactions.

Frequently Asked Questions

Austedo is used to treat tardive dyskinesia, an involuntary movement disorder often caused by long-term antipsychotic use, and chorea associated with Huntington's disease. It works by reducing dopamine availability in the brain to decrease excessive involuntary movements. Austedo is an oral medication prescribed when other treatment options are ineffective or not tolerated.

Austedo is administered orally as a tablet, typically starting at 6 mg daily and titrated based on therapeutic response and tolerability, up to a maximum of 48 mg daily. Dosing should be individualized and adjusted gradually to minimize adverse effects. Patients should take Austedo consistently as prescribed by their healthcare provider.

Common side effects include sedation, akathisia (restlessness), depression, insomnia, and parkinsonism. Most side effects are dose-dependent and may improve with dose adjustment or continued use. Serious side effects such as suicidality and neuroleptic malignant syndrome require immediate medical attention.

Austedo is manufactured by Teva Neuroscience, Inc., a subsidiary of Teva Pharmaceutical Industries specializing in neurological medications.

Yes, Austedo has received FDA orphan drug designation for both tardive dyskinesia and Huntington's disease chorea. This designation recognizes its therapeutic importance in treating rare conditions affecting a limited patient population and provides regulatory incentives for development and commercialization.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.